Selank peptide is a short, synthetic analogue of tuftsin with potent anti-anxiety effects. It has been shown to improve memory, enhance learning, and positively influence pain perception. As a nootropic and anxiolytic compound, Selank is of increasing interest in neurological and cognitive research.
$50 USD
Out of stock
Not for human or veterinary use. Made in USA
This product is intended as a research chemical only. Not for human use. Peptides will arrive in a lyophilized (powder) form for maximum stability.
Selank is a short peptide with both nootropic and anxiolytic properties. It is a synthetic analogue of tuftsin, a naturally occurring immunomodulatory peptide, and influences IL-6, T helper cells, monoamine neurotransmitters, and brain-derived neurotrophic factor (BDNF). Selank differs from tuftsin by having four additional amino acids, which enhance its metabolic stability and half-life. It has been clinically tested as a potential treatment for generalized anxiety disorder.
Peptide Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
Molecular Formula: C₃₃H₅₇N₁₁O₉
Molecular Weight: 751.887 g/mol
PubChem CID: 11765600
CAS Number: 129954-34-3
Synonyms: Selanc
Selank is a synthetic peptide with potent anxiolytic, neuroprotective, and cognitive-enhancing properties. Developed as an analogue of tuftsin, Selank modulates GABAergic signaling, demonstrating effects similar to benzodiazepines but without the risks of dependence or withdrawal. Research shows it alters the expression of over 50 genes tied to GABA neurotransmission and inhibits enkephalin-degrading enzymes, potentially enhancing the body’s natural stress-relief mechanisms. Selank also influences the immune system by downregulating pro-inflammatory cytokines like IL-6 and modulating genes involved in immune development. Studies in rats and humans indicate it improves memory, learning, and cognitive recovery following brain injury, likely by impacting hippocampal gene expression. Additionally, Selank shows promise in alleviating pain and fatigue through enkephalin preservation. It is well-tolerated in preclinical models and is available strictly for research purposes.
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Dr. Petr Slominsky, whose body of work includes 169 research publications with over 800 citations, has authored 12 studies exploring the diverse effects of Selank. His research focuses on areas such as anxiety reduction, transcriptional changes in the hippocampus, and gene expression related to chemokines, cytokines, and their receptors. He is particularly noted for his interest in Selank’s epigenetic impact and its implications for disease-state pathologies. While Dr. Slominsky is referenced here to acknowledge his significant contributions to Selank research, he is not affiliated with or endorsing Peptide Sciences or the sale or use of this product in any form.
A. Volkova et al., “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission,” Front. Pharmacol., vol. 7, Feb. 2016. PubMed
A. Kasian et al., “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats,” Behavioural Neurology, 2017. Link
A. A. Zozulya et al., “The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity,” Bull. Exp. Biol. Med., vol. 131, no. 4, pp. 315–317, Apr. 2001. PubMed
O. Y. Sokolov, V. K. Meshavkin, N. V. Kost, and A. A. Zozulya, “Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions,” Bull. Exp. Biol. Med. PubMed
O. N. Uchakina et al., “[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 108, no. 5, pp. 71–75, 2008. PubMed
A. A. Zozulia et al., “[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 108, no. 4, pp. 38–48, 2008. PubMed
T. Kolomin, M. Shadrina, L. Andreeva, P. Slominsky, S. Limborska, and N. Myasoedov, “Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank,” Regul. Pept., vol. 170, no. 1–3, pp. 18–23, Oct. 2011. PubMed
T. I. Agapova et al., “[Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex],” Mol. Genet. Mikrobiol. Virusol., no. 3, pp. 28–32, 2008. PubMed
T. P. Semenova, I. I. Kozlovskiĭ, N. M. Zakharova, and M. M. Kozlovskaia, “[Experimental optimization of learning and memory processes by selank],” Eksp. Klin. Farmakol., vol. 73, no. 8, pp. 2–5, Aug. 2010. PubMed
T. A. Kolomin et al., “[c],” Zh. Vyssh. Nerv. Deiat. Im. I. P. Pavlova, vol. 63, no. 3, pp. 365–374, Jun. 2013.
T. P. Semenova, M. M. Kozlovskaya, N. M. Zakharova, I. I. Kozlovskii, and A. V. Zuikov, “Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny,” Bull. Exp. Biol. Med., vol. 144, no. PubMed
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.
For further information on proper storage techniques, click the link below:
Peptide Storage Information
This product is intended as a research chemical only. Not for human use. Peptides will arrive in a lyophilized (powder) form for maximum stability.
Selank is a short peptide with both nootropic and anxiolytic properties. It is a synthetic analogue of tuftsin, a naturally occurring immunomodulatory peptide, and influences IL-6, T helper cells, monoamine neurotransmitters, and brain-derived neurotrophic factor (BDNF). Selank differs from tuftsin by having four additional amino acids, which enhance its metabolic stability and half-life. It has been clinically tested as a potential treatment for generalized anxiety disorder.
Peptide Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
Molecular Formula: C₃₃H₅₇N₁₁O₉
Molecular Weight: 751.887 g/mol
PubChem CID: 11765600
CAS Number: 129954-34-3
Synonyms: Selanc
Selank is a synthetic peptide with potent anxiolytic, neuroprotective, and cognitive-enhancing properties. Developed as an analogue of tuftsin, Selank modulates GABAergic signaling, demonstrating effects similar to benzodiazepines but without the risks of dependence or withdrawal. Research shows it alters the expression of over 50 genes tied to GABA neurotransmission and inhibits enkephalin-degrading enzymes, potentially enhancing the body’s natural stress-relief mechanisms. Selank also influences the immune system by downregulating pro-inflammatory cytokines like IL-6 and modulating genes involved in immune development. Studies in rats and humans indicate it improves memory, learning, and cognitive recovery following brain injury, likely by impacting hippocampal gene expression. Additionally, Selank shows promise in alleviating pain and fatigue through enkephalin preservation. It is well-tolerated in preclinical models and is available strictly for research purposes.
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Dr. Petr Slominsky, whose body of work includes 169 research publications with over 800 citations, has authored 12 studies exploring the diverse effects of Selank. His research focuses on areas such as anxiety reduction, transcriptional changes in the hippocampus, and gene expression related to chemokines, cytokines, and their receptors. He is particularly noted for his interest in Selank’s epigenetic impact and its implications for disease-state pathologies. While Dr. Slominsky is referenced here to acknowledge his significant contributions to Selank research, he is not affiliated with or endorsing Peptide Sciences or the sale or use of this product in any form.
A. Volkova et al., “Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission,” Front. Pharmacol., vol. 7, Feb. 2016. PubMed
A. Kasian et al., “Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats,” Behavioural Neurology, 2017. Link
A. A. Zozulya et al., “The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity,” Bull. Exp. Biol. Med., vol. 131, no. 4, pp. 315–317, Apr. 2001. PubMed
O. Y. Sokolov, V. K. Meshavkin, N. V. Kost, and A. A. Zozulya, “Effects of Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions,” Bull. Exp. Biol. Med. PubMed
O. N. Uchakina et al., “[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 108, no. 5, pp. 71–75, 2008. PubMed
A. A. Zozulia et al., “[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia],” Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova, vol. 108, no. 4, pp. 38–48, 2008. PubMed
T. Kolomin, M. Shadrina, L. Andreeva, P. Slominsky, S. Limborska, and N. Myasoedov, “Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank,” Regul. Pept., vol. 170, no. 1–3, pp. 18–23, Oct. 2011. PubMed
T. I. Agapova et al., “[Effect of semax on the temporary dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex],” Mol. Genet. Mikrobiol. Virusol., no. 3, pp. 28–32, 2008. PubMed
T. P. Semenova, I. I. Kozlovskiĭ, N. M. Zakharova, and M. M. Kozlovskaia, “[Experimental optimization of learning and memory processes by selank],” Eksp. Klin. Farmakol., vol. 73, no. 8, pp. 2–5, Aug. 2010. PubMed
T. A. Kolomin et al., “[c],” Zh. Vyssh. Nerv. Deiat. Im. I. P. Pavlova, vol. 63, no. 3, pp. 365–374, Jun. 2013.
T. P. Semenova, M. M. Kozlovskaya, N. M. Zakharova, I. I. Kozlovskii, and A. V. Zuikov, “Effect of selank on cognitive processes after damage inflicted to the cerebral catecholamine system during early ontogeny,” Bull. Exp. Biol. Med., vol. 144, no. PubMed
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you’re ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4C (39F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
However, for longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80C (-112F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide’s stability.
For further information on proper storage techniques, click the link below:
Peptide Storage Information
Receive all the latest information on events, sales, & offers.
Mon - Fri 9AM - 4PM PST
Mon - Fri (Excluding holidays)
Orders placed and paid after 12PM PST are shipped the following business day
© 2025
Ai-Peptides.com. All Rights Reserved.
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind.
The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
Ai-Peptides is a chemical supplier. Ai-Peptides is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. AiPeptides is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
